Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma
- 67 Downloads
Objectives: To evaluate the toxicity and efficacy of interferon and thalidomide combination in a phase II clinical trial.
Patients and methods: Eligibility included metastatic renal cancer with a maximum of two prior regimens, performance status of 0‐2 and adequate renal, hepatic and bone marrow function.
Results: Twenty patients were enrolled on this phase II trial. Median age was 60.5 years (Range: 39–75 years). 17 patients had visceral metastases (lung/liver/both) and 3 patients had lymph node only metastases. A total of 26 cycles of 4 weeks each were administered; median of 1 cycle and range from 0‐9 cycles. The therapy was poorly tolerated with grade 3 adverse events noted in 12 (60%) of the 20 patients. No objective responses were noted. Of the 14 response evaluable patients, one had an unconfirmed response (38% decrease in size) and one had prolonged disease stabilization for 10 months. The median time to progression was 1.0 month and median survival was 2.8 months. Pre and post therapy PET scans were performed nine weeks apart on one patient. The mean standardized uptake values (SUV) declined from 1.45 (SUV min-max 0.89–1.76) to 1.12 (SUV min-max 0.55–1.47), denoting anti vascular effect. The patient did not have an objective response but had a disease stabilization sustained for 10 months.
Conclusion: The combination of interferon and thalidomide has minimal efficacy and considerable toxicity which makes this combination unworthy of future investigation in metastatic renal cancer.
KeywordsRenal cancer Immunotherapy Phase II clinical trial Interferon Thalidomide
Supported in part by a grant from the Dept. of Internal Medicine, Wayne State University, Detroit MI, by Schering Inc., Celgene Corp, and by NIH Cancer Center Support Grant CA-22453
- 1.Sokoloff MH, Figlin RA, de Kernion JB, Belldegrun AS (1997) Systemic immunotherapy for genitourinary neoplasms. In: Raghavan D, Scher HI, Leibel SA, Lange P (eds) Principles and practice of genitourinary oncology, Lippincott-Raven, Philadelphia, pp 869–883Google Scholar
- 2.Motzer RJ, Vogelzang NJ (1997) Chemotherapy for renal cell carcinoma. In: Raghavan D, Scher HI, Leibel SA, Lange P (eds) Principles and practice of genitourinary oncology, Lippincott-Raven, Philadelphia, pp 885–896Google Scholar
- 4.Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bukowski RM (2005) Randomized Phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc ASCO (abstract #4510)Google Scholar
- 5.Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukowski RM, George DJ, Kim ST, Baum CM, The SU11248 Study Group (2005) Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc ASCO (abstract #4508)Google Scholar
- 7.Sidky YA, Borden EC (1987) Inhibition of angiogenesis by interferons: effects on tumor and lymphocyte induced vascular responses. Cancer 47:5155–5161Google Scholar
- 12.Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 338:1272–1278PubMedCrossRefGoogle Scholar
- 15.Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC (1995) Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. British J Cancer 72:339–343Google Scholar
- 18.Amato RJ (2002) Thalidomide: an antineoplastic agent. Curr Oncol Rep Jan 4:56–62Google Scholar
- 21.Casella G (1987) Refining binomial confidence intervals. Canadian J Statistics 14:113–129Google Scholar
- 22.Mehta C, Patel N (1999) StatXact 5: statistical software for exact nonparametric inference, user manual. Cytel Software CorporationGoogle Scholar
- 23.Lee E (1992) Statistical methods for survival data analysis, 2nd edn. Wiley & Sons, IncGoogle Scholar
- 28.Gordon MS, Manola J, Fairclough D, Cella D, Richardson R, Sosman J, Kasimis B, Dutcher JP, Wilding G (2004) Low dose interferon-α2b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC). Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS). A phase III study of the Eastern Cooperative Oncology Group (E2898). Proc ASCO (abstract #4516)Google Scholar
- 30.Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, O'Toole T, Park Y, Moore L (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). Proc ASCOLB (abstract #4)Google Scholar
- 32.Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512PubMedCrossRefGoogle Scholar